Understanding Delivery Methods Choosing the right delivery method is essential for maximizing the benefits of IGF-1 LR3
Unlike other GH-releasing peptides such as GHRP-2 or GHRP-6, Ipamorelin demonstrates exceptionally low cross-reactivity with other pituitary receptors
Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects
Compound K attenuates stromal cell-derived growth factor 1 (SDF-1)-induced migration of C6 glioma cells
Practical Implications of No IGF-1 Elevation: The absence of IGF-1 stimulation makes AOD-9604 suitable for populations who need to avoid IGF-1 elevation, including individuals with personal or family history of hormone-sensitive cancers, those concerned about accelerated aging through growth pathway activation, people seeking fat loss without anabolic muscle-building effects, individuals who have contraindications to growth hormone therapy, and those undergoing screening or monitoring where IGF-1 elevation would be problematic
In a Phase 1 clinical trial, AMG133 demonstrated significant dose-dependent weight loss effects, achieving up to a 14.5% reduction in body weight compared to a 1.5% reduction for the placebo group on day 85